Drug Discovery Tools to Examine Neuroinflammation Signalling in Human iPSC-Derived Microglia
-
- Huge challenges exist in central nervous system (CNS) drug discovery: There is significant unmet need across the spectrum of CNS disorders.
- There has been renewed interest in developing novel CNS therapeutics and innovation with advances in human iPSC cell models, biomarker research and understanding immune system contribution.
- Neuroinflammation is proposed to play a major role in across the spectrum of CNS disorders, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
- Microglia, the resident immune cells of the CNS, are key mediators of neuroinflammation in the CNS. Recently, recently there has been a significant effort directed towards developing human in vitro iPSC-microglia cell models, with the aim to improve the understanding of disease mechanisms and to increase clinical translation.
- At MDC, we have generated functional iPSC-microglia that respond to inflammatory stimuli.
- We have established lentiviral based reporters to interrogate inflammation signalling and inflammasome activation for drug discovery projects.
- Together these represent invaluable drug discovery tools for investigating CNS and inflammatory diseases.
Drug Discovery Tools to Examine Neuroinflammation Signalling in Human iPSC-Derived Microglia
This poster was created for ELRIG Drug Discovery 2022.
